Cambridge ‘hitmen’ have drug targets in their sights
Cambridge UK medical technology business Domainex has partnered with Cresset Discovery Services in a chemistry-biology play designed to identify novel hit compounds against drug discovery targets.
The collaboration will give clients fully-integrated access to the expertise of Domainex in protein expression, biochemical assays, hit identification, computational and medicinal chemistry and to Cresset’s approach to hit identification and drug design using its proprietary computational technologies.
Eddy Littler (pictured), CEO at Domainex said: “The combination of our drug discovery skills and the computational chemistry technologies and expertise of Cresset means that together we can offer customers an unrivalled capability to identify novel hit compounds against important drug targets – and to progress these all the way to candidate drugs.
“In particular, Cresset’s patented field point technology and associated ligand-based approaches to targets such as GPCRs and ion-channels will perfectly complement Domainex’s own expertise in target areas such as enzymes and protein-protein interactions.
“We recently announced that we will be moving our laboratories to a new and larger facility at Chesterford Research Park. Our alliance with Cresset provides a complementary expansion of the range of computational technologies that we can apply to client projects and directly integrates with our skills in assay development, medicinal and computational chemistry.”
Rob Scoffin, chief executive officer of Cresset, added: “We are very excited about the opportunity to partner with another world-class research services company to offer unrivalled capabilities in drug discovery and development.
“We are able to provide integrated services which will include access to Cresset’s existing applications as well as our pipeline of cutting edge computational science and yet-to-be-commercialised methods.”